BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reich M, Spomer L, Klindt C, Fuchs K, Stindt J, Deutschmann K, Höhne J, Liaskou E, Hov JR, Karlsen TH, Beuers U, Verheij J, Ferreira-Gonzalez S, Hirschfield G, Forbes SJ, Schramm C, Esposito I, Nierhoff D, Fickert P, Fuchs CD, Trauner M, García-Beccaria M, Gabernet G, Nahnsen S, Mallm JP, Vogel M, Schoonjans K, Lautwein T, Köhrer K, Häussinger D, Luedde T, Heikenwalder M, Keitel V. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. J Hepatol 2021;75:634-46. [PMID: 33872692 DOI: 10.1016/j.jhep.2021.03.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Semin Immunopathol 2022. [PMID: 35415765 DOI: 10.1007/s00281-022-00935-7] [Reference Citation Analysis]
2 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Gertzen CGW, Gohlke H, Häussinger D, Herebian D, Keitel V, Kubitz R, Mayatepek E, Schmitt L. The many facets of bile acids in the physiology and pathophysiology of the human liver. Biol Chem 2021;402:1047-62. [PMID: 34049433 DOI: 10.1515/hsz-2021-0156] [Reference Citation Analysis]
4 Chiang JY, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Molecular and Cellular Endocrinology 2022. [DOI: 10.1016/j.mce.2022.111618] [Reference Citation Analysis]
5 Gallo C, Howardson BO, Cristoferi L, Carbone M, Gershwin ME, Invernizzi P. An Update on Novel Pharmacological Agents for Primary Sclerosing Cholangitis. Expert Opin Ther Targets 2022. [PMID: 35040733 DOI: 10.1080/14728222.2022.2030707] [Reference Citation Analysis]
6 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Reference Citation Analysis]
7 Herta T, Kersten R, Chang JC, Hubers L, Go S, Tolenaars D, Paulusma CC, Nathanson MH, Elferink RO, van de Graaf SFJ, Beuers U. Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection. J Hepatol 2021:S0168-8278(21)02116-4. [PMID: 34718050 DOI: 10.1016/j.jhep.2021.10.009] [Reference Citation Analysis]
8 Li R, Chen C, Liu B, Shi W, Shimizu K, Zhang C. Bryodulcosigenin a natural cucurbitane-type triterpenoid attenuates dextran sulfate sodium (DSS)-induced colitis in mice. Phytomedicine 2022;94:153814. [PMID: 34798522 DOI: 10.1016/j.phymed.2021.153814] [Reference Citation Analysis]